Sai Life Sciences Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/qndza0589iw4r0sx5jfddkhu.pdf

Key Takeaways


CDMO Performance & Drivers

Krishna Kanumuri: "I would say right now, at least visibility is strong at this point. I don't know if it's always going to be the case, but this investment is based on a better visibility than we had done in the past."

CRO Business & Discovery


China-Plus-One & Competitive Positioning

Krishna Kanumuri: "The one issue which has come up in China, which is actually moving customers away, is IP issues have come up in China, primarily because China has become a competitor for them on the Discovery side."

Capacity Expansion & Capex


Demand Environment & Biotech Funding


Margins & Profitability


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth15% average growth rate3–5 year horizon
Manufacturing capacity80% increase from 1,200–1,300 KL baseBy 2027
First new production block200 KL onlineQ3 FY27
Second new production blockAdditional 250 KL onlineEnd of FY27
Process R&D capacityNearly double currentBy next year
Discovery space30% additional spaceEnd of current fiscal year
Capex (current year)₹700 crFY26
CRO client expansion benefit30% expansion flows throughImmediately from Q2
EBITDA margin target28–30%As revenues grow (no date)

Key Metrics

MetricQ1 FY26
Revenue₹496 cr, +77% YoY vs ₹218 cr in Q1 FY25
CDMO revenue₹314 cr, +113% YoY vs ₹148 cr in Q1 FY25
CRO revenue₹182 cr, +38% YoY vs ₹132 cr in Q1 FY25
EBITDA₹125 cr, +305% YoY vs ₹31 cr in Q1 FY25
EBITDA margin25%, +14 ppt YoY improvement
PAT₹60 cr, vs loss of ₹13 cr in Q1 FY25
Capex₹134 cr in Q1; full-year FY26 plan of ₹700 cr
CDMO capacity utilization~77% at end of Q1; 70-75% considered decently fully utilized
CDMO capacity added100 KL commissioned at end of Q1
CDMO capacity base~600 KL at end of FY25; 550 KL addition planned, taking total to ~1,150 KL by H2 FY27
Phase III pipeline6 molecules, down from 10; 2 moved to commercial, 2 dropped out due to clinical trial failure
Scientists onboarded250+ during the quarter
Client and regulatory audits11 completed across sites during the quarter
Top 10 customer concentration~40% of revenue, reported on a full-year basis
CRO customer split38% Big Pharma, 62% Biotech